The relationship between FDG uptake in PET scans and biological behavior in breast cancer

Shimoda, Wataru; Hayashi, Mitsuhiro; Murakami, Koji; Oyama, Tetsunari; Sunagawa, Masakatsu

doi:10.2325/jbcs.14.260

Cited by 90 publications

(66 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Other previous studies are consistent with our result [14,16,21,32]. It has been reported that SUVmax of breast cancer shows a linear relationship in T1-T3 tumors and correlates with tumor size.…”

Section: Discussionsupporting

confidence: 94%

The Relationship Between Estrogen Receptor, Progesterone Receptor and Human Epidermal Growth Factor Receptor 2 Expression of Breast Cancer and the Retention Index in Dual Phase 18F-FDG PET/CT

Moon

Noh

Kim

et al. 2016

Nucl Med Mol Imaging

View full text Add to dashboard Cite

Purpose This study investigates the correlation of retention index (RI) using the dual phase FDG PET/CT scan with the breast cancer biomarkers. Methods A total of 55 patients with breast cancer underwent dual phase FDG PET/CT scans (60 and 120 min after FDG injection) before treatment. SUVmax and SUVmean of the primary breast tumors were measured, then the percent change of SUVmax and SUVmean between the two scans were calculated, and denoted as RImax and RImean, respectively. After the surgical resection of the breast tumor, the status of biomarkers (ER, PR, and HER-2) was evaluated in the postsurgical specimen.

show abstract

Section: Discussionsupporting

confidence: 94%

The Relationship Between Estrogen Receptor, Progesterone Receptor and Human Epidermal Growth Factor Receptor 2 Expression of Breast Cancer and the Retention Index in Dual Phase 18F-FDG PET/CT

Moon

Noh

Kim

et al. 2016

Nucl Med Mol Imaging

View full text Add to dashboard Cite

show abstract

“…Akin to others [4,6,8,10,34], our study revealed that primary malignant lesions with higher histopathologic grade and expression of Ki-67 showed significantly higher SUVmax (4.3 vs. 7.5 vs. 9.3; 4.6 vs. 8.7, respectively p < 0.001).…”

Section: Discussionmentioning

confidence: 72%

“…Most of the previous studies mainly assessed the correlation between each histopathologic factor and SUVmax [5][6][7][8][9][10][11][12]. Garcia et al [13] reported that semiquantitative parameters of F-18 FDG PET/CT showed statistically significant differences among the molecular subtypes according to the recommendations of St. Gallen consensus meeting 2011.…”

Section: Introductionmentioning

confidence: 99%

Correlation of Molecular Subtypes of Invasive Ductal Carcinoma of Breast with Glucose Metabolism in FDG PET/CT: Based on the Recommendations of the St. Gallen Consensus Meeting 2013

Lee

Bae

Park³

et al. 2016

Nucl Med Mol Imaging

View full text Add to dashboard Cite

Purpose This study aimed to investigate the relationship between the SUVmax of primary breast cancer lesions and the molecular subtypes based on the recommendations of the St. Gallen consensus meeting 2013. Methods Clinical records of patients who underwent F-18 FDG PET/CT for initial staging of invasive ductal carcinoma (IDC) of the breast were reviewed. A total of 183 patients were included. SUVmax was correlated with the molecular subtypes defined by the St. Gallen Consensus Meeting 2013, i.e., luminal A-like (LA), luminal B-like HER2 negative (LBHER2-), luminal Blike HER2 positive (LBHER2+), HER2 positive (HER2+), and triple negative (TN), and with the clinicohistopathologic characteristics. Results The molecular subtype was LA in 38 patients, LBHER2-in 72, LBHER2+ in 21, HER2+ in 30, and TN in 22. The mean SUVmax in the LA, LBHER2-, LBHER2+, HER2+, and TN groups were 4.5 ± 2.3, 7.2 ± 4.9, 7.2 ± 4.3, 10.2 ± 5.5, and 8.8 ± 7.1, respectively. Although SUVmax differed significantly among these subtypes (p < 0.001), the values showed a wide overlap. Optimal cut-off SUVmax to differentiate LA from LBHER2-, LBHER2+, HER2+ and TN were 5.9, 5.8, 7.5, and 10.2 respectively, with area under curve (AUC) of 0.648, 0.709, 0.833, and 0.697 respectively. The cut-off value of 5.9 yielded the highest accuracy for differentiation between the LA and non-LA subtypes, with sensitivity, specificity, and AUC of 79.4 %, 57.9 %, and 0.704 respectively. Conclusion The SUVmax showed a significant correlation with the molecular subtype. Although SUVmax measurements could be used along with immunohistochemical analysis for differentiating between molecular subtypes, its application to individual patients may be limited due to the wide overlaps in SUVmax.

show abstract

“…The initial role of 18 FDG PET was in the differentiation between benign and malignant lesions, especially in indeterminate solitary pulmonary nodules (Lowe et al, 1998) with further exploration into grading and prognosis assessment of various tumours (Dimitrakopoulou-Strauss et al, 2001; Shimoda et al, 2007). Standardised uptake values have been shown to be reliable in differentiating between benign and malignant lesions in a number of situations, but in others visual analysis has been reported to be equivalent (Lowe et al, 1994).…”

Section: Clinical Applications Tissue Differentiation and Tumour Gradingmentioning

confidence: 99%

“…There is less evidence on the use of PET to determine grade of malignancy, with few dynamic studies reported. However, there is some evidence that 18 FDG PET correlates with tumour grade and infers prognosis in some tumour types, examples having been reported in bone, breast and brain tumours, among others (DimitrakopoulouStrauss et al, 2001;Borbely et al, 2006;Shimoda et al, 2007).…”

Section: Clinical Applications Tissue Differentiation and Tumour Gradingmentioning

confidence: 99%

Quantitative techniques in 18FDG PET scanning in oncology

Castell

Cook

2008

Br J Cancer

View full text Add to dashboard Cite

The clinical applications of 18 F-fluoro-2-deoxyglucose ( 18 FDG) positron emission tomography (PET) (Figure 1). The information derived from 18 FDG PET scans is more frequently becoming the basis for decisions on subsequent management, such as the cessation or switching of chemotherapy regimes and the addition or modification of radiotherapy. It is also used clinically to establish the diagnosis of relapse following treatment.There is a wealth of literature reporting on the role of 18 FDG PET in malignancy, showing a wide range of associated sensitivities and specificities; frequently showing greater accuracy than other forms of conventional imaging in a number of tumour types. One of the explanations for the range of reported results may be due to the variability of scanning protocols and analytic techniques used. The analytic techniques range from simple visual qualitative assessment and semiquantitative methods, for example, standardised uptake value (SUV) measurement, to full kinetic analysis with compartmental modelling, for example, nonlinear regression analysis (NLR). A variety of analytical methods have been proposed that need to be validated for different tumour types and for assessing therapeutic response. While simple qualitative techniques are sufficient for many routine clinical examinations, an increase in the use of PET with 18 FDG, and also novel tracers reflecting different pharmacodynamic end points in clinical trials, often necessitates a more complex and quantitative approach.

show abstract

The relationship between FDG uptake in PET scans and biological behavior in breast cancer

Cited by 90 publications

References 16 publications

The Relationship Between Estrogen Receptor, Progesterone Receptor and Human Epidermal Growth Factor Receptor 2 Expression of Breast Cancer and the Retention Index in Dual Phase 18F-FDG PET/CT

The Relationship Between Estrogen Receptor, Progesterone Receptor and Human Epidermal Growth Factor Receptor 2 Expression of Breast Cancer and the Retention Index in Dual Phase 18F-FDG PET/CT

Correlation of Molecular Subtypes of Invasive Ductal Carcinoma of Breast with Glucose Metabolism in FDG PET/CT: Based on the Recommendations of the St. Gallen Consensus Meeting 2013

Quantitative techniques in 18FDG PET scanning in oncology

Contact Info

Product

Resources

About